Description 【18 March 2019, Hong Kong】 CanSino Biologics Inc. (康希諾生物股份公司) (“CanSinoBIO” or the “Company”; stock code: 6185), announces the proposed listing of its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) today.

Description [28 March 2019, Hong Kong] CanSino Biologics Inc. (“CanSinoBio” or “Company”, stock code: 6185.HK), was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) and the dealing of its share commenced trading on 28 March 2019.

Description TIANJIN, CHINA, April 19, 2019, CanSino Biologics Inc. (CanSinoBIO, 6185.HK) announces that it received the National Medical Products Administration’s (NMPA) permission for its PCV13i, a candidate 13-valent pneumococcal conjugate vaccine, by to start human clinical trials.

Description TIANJIN, CHINA, June 20, 2019, CANSINO BIOLOGICS INC. (CanSinoBIO, HK6185) announced today that it has entered into a Research and Development Collaboratio

Description TIANJIN, CHINA, August 26, 2019, China’s peacekeepers got Ebola vaccine shots earlier in the month before departure for their peace missions in the Democratic Republic of Congo (DRC), where the deadly disease has been continuing for over a year since August 2018 and has caused deaths of more than 1900 people according to the latest update by World Health Organization (WHO).

Description TIANJIN, CHINA, November 22th, 2019, CanSino Biologics Inc. (“CanSinoBIO”, HK6185) announced today that China National Medical Products Administration (NMPA) has accepted Company’s New Drug Application (NDA) for its investigational quadrivalent meningococcal (serogroups A, C, W-135 and Y) conjugate vaccine, MenhyciaTM by registered trade name.

Description TIANJIN, CHINA, November 26th, 2019, CanSino Biologics Inc. (“CanSinoBIO”, HK6185) signed a Memorandum on Reciprocal Developmental Programs with Tianjin Medical Products Administration (TMPA), in an effort to strengthen the regulator’s capacity and capabilities on routine surveillance inspections to vaccine manufacturers.

Description TIANJIN, CHINA, December 16, 2019, CanSino Biologics Inc. (“CanSinoBIO”, HK6185) announced today that the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has granted Priority Review designation to the Company’s NDA for its investigational quadrivalent meningococcal (serogroups A, C, W-135 and Y) conjugate vaccine (MenhyciaTM), according to the latest CDE announcement on its website.

Description TIANJIN, CHINA, January 2, 2020, CanSino Biologics Inc. (“CanSinoBIO” or the “Company”, 6185.HK) announced the appointment of Dr. Pierre Armand Morgon as Senior Vice President responsible for international business operation. The appointment indicated a further step forward in the Company’s commitment to global development and growth.

Description TIANJIN, CHINA, March 17, 2020, CanSino Biologics Inc. (“CanSinoBIO”, HK6185), an innovative biopharmaceutical company dedicated to vaccine R&D and commercialization, announced today that its Recombinant Novel Coronavirus Vaccine ...